Caplacizumab

Generic name: Caplacizumab
Brand names: Cablivi
Dosage form: injectable kit (yhdp 11 mg)
Drug class: Platelet aggregation inhibitors

Usage of Caplacizumab

Caplacizumab is used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Caplacizumab is given together with immunosuppressant medication and plasma exchange (transfusion).

Caplacizumab may also be used for purposes not listed in this medication guide.

Caplacizumab side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Caplacizumab may cause serious side effects. Call your doctor at once if you have:

easy bruising or bleeding (nosebleeds, bleeding gums);

unusual vaginal bleeding;

any bleeding that will not stop; or

signs of stomach bleeding--bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.

Common side effects of caplacizumab may include:

nosebleeds, bleeding gums; or

headache.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Caplacizumab

You should not use caplacizumab if you are allergic to it.

Tell your doctor if you have ever had a bleeding or blood clotting disorder such as hemophilia.

Follow your doctor's instructions about using caplacizumab if you are pregnant. Caplacizumab may increase the risk of bleeding in both mother and baby. However, the benefit of treating aTTP in the mother during pregnancy may outweigh those risks. Tell your doctor right away if you become pregnant.

It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.

Relate drugs

How to use Caplacizumab

Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura:

Initial dose:-First day of treatment: 11 mg bolus IV injection at least 15 minutes prior to plasma exchange followed by an 11 mg suBCutaneous injection after completion of plasma exchange on Day 1Maintenance dose:-Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once a day following plasma exchange-Treatment after plasma exchange period: 11 mg subcutaneous injection once a day continuing for 30 days following the last daily plasma exchange. If after initial treatment course sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.Comments:-Discontinue this drug if the patient experiences more than 2 recurrences of acquired thrombotic thrombocytopenic purpura (aTTP) during treatment with this drug.-Withhold this drug 7 days prior to elective surgery, dental procedures, or other invasive interventions.Use: Treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy

Warnings

Caplacizumab can increase your risk of bleeding. Call your doctor if you have unusual bruising or bleeding, or any bleeding that will not stop.

What other drugs will affect Caplacizumab

Tell your doctor about all your other medicines, especially:

a blood thinner--warfarin, Coumadin, Jantoven; or

any medicine used to treat or prevent blood clots.

This list is not complete. Other drugs may affect caplacizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.